Clinical studies of CD47 antibodies or targeted drugs for MDS or AML have been carried out, but most have been based on blocking CD47 expression to restore the phagocytosis of foreign cells by macrophages. This evidence concerns the gene CD47 and myelodysplastic syndrome.